| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331, 2020 | 1052 | 2020 |
| The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4‐related disease ZS Wallace, RP Naden, S Chari, H Choi, E Della‐Torre, JF Dicaire, ... Arthritis & Rheumatology 72 (1), 7-19, 2020 | 878 | 2020 |
| Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study C Campochiaro, E Della-Torre, G Cavalli, G De Luca, M Ripa, N Boffini, ... European journal of internal medicine 76, 43-49, 2020 | 449 | 2020 |
| Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors M Ripa, L Galli, A Poli, C Oltolini, V Spagnuolo, A Mastrangelo, C Muccini, ... Clinical Microbiology and Infection 27 (3), 451-457, 2021 | 368 | 2021 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 267 | 2021 |
| Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study E Della-Torre, C Campochiaro, G Cavalli, G De Luca, A Napolitano, ... Annals of the rheumatic diseases 79 (10), 1277-1285, 2020 | 256 | 2020 |
| GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473, 2020 | 226 | 2020 |
| The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases G Cavalli, B Guglielmi, A Berti, C Campochiaro, MG Sabbadini, L Dagna Annals of the rheumatic diseases 72 (10), 1691-1695, 2013 | 213 | 2013 |
| Arrhythmias in myocarditis: state of the art G Peretto, S Sala, S Rizzo, G De Luca, C Campochiaro, S Sartorelli, ... Heart rhythm 16 (5), 793-801, 2019 | 203 | 2019 |
| Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation G Peretto, S Sala, S Rizzo, A Palmisano, A Esposito, F De Cobelli, ... Journal of the American College of Cardiology 75 (9), 1046-1057, 2020 | 202 | 2020 |
| Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study G Cavalli, A Larcher, A Tomelleri, C Campochiaro, E Della-Torre, ... The Lancet Rheumatology 3 (4), e253-e261, 2021 | 168 | 2021 |
| IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients C Campochiaro, GA Ramirez, EP Bozzolo, M Lanzillotta, A Berti, ... Scandinavian journal of rheumatology 45 (2), 135-145, 2016 | 164 | 2016 |
| Erdheim-chester disease C Campochiaro, A Tomelleri, G Cavalli, A Berti, L Dagna European journal of internal medicine 26 (4), 223-229, 2015 | 148 | 2015 |
| An International multispecialty validation study of the IgG4‐related disease responder index ZS Wallace, A Khosroshahi, MD Carruthers, CA Perugino, H Choi, ... Arthritis care & research 70 (11), 1671-1678, 2018 | 140 | 2018 |
| BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease MG Cangi, R Biavasco, G Cavalli, G Grassini, E Dal-Cin, C Campochiaro, ... Annals of the rheumatic diseases 74 (8), 1596-1602, 2015 | 136 | 2015 |
| Prevalence, characteristics, risk factors, and outcomes of invasively ventilated COVID-19 patients with acute kidney injury and renal replacement therapy EV Fominskiy, AM Scandroglio, G Monti, MG Calabro, G Landoni, ... Blood purification 50 (1), 102-109, 2021 | 120 | 2021 |
| Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab A Berti, G Cavalli, C Campochiaro, B Guglielmi, E Baldissera, S Cappio, ... Seminars in Arthritis and Rheumatism 45 (1), 48-54, 2015 | 91 | 2015 |
| Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: a case report and review of the literature E Della-Torre, M Lanzillotta, C Campochiaro, E Bozzalla, E Bozzolo, ... Medicine 95 (34), e4633, 2016 | 82 | 2016 |
| Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement G Natalello, G De Luca, L Gigante, C Campochiaro, E De Lorenzis, ... Microvascular research 133, 104071, 2021 | 81 | 2021 |
| Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes M Lanzillotta, C Campochiaro, G Mancuso, GA Ramirez, G Capurso, ... Rheumatology 59 (9), 2435-2442, 2020 | 78 | 2020 |
